Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - inactivated rabies virus vaccine (vet.) - suspension for injection (sc/im) - formulation: each 1 ml (dose) contains: rabies virus (pasteur riv strain).............. > 2i.u. iu-international units

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - measles vaccine, schwarz strain 1000 ccid50 (not less than); mumps virus, live attenuated, rit 4385 5012 ccid50 (not less than);  ; rubella virus, wistar ra27/3 strain 1000 ccid50 (not less than) - powder for injection with diluent - 0.5 ml - active: measles vaccine, schwarz strain 1000 ccid50 (not less than) mumps virus, live attenuated, rit 4385 5012 ccid50 (not less than)   rubella virus, wistar ra27/3 strain 1000 ccid50 (not less than) excipient: amino acids lactose mannitol sorbitol water for injection - priorix is indicated for the active immunisation against measles, mumps and rubella.

United States - English - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually an immunization series is initiated and completed with 1 vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv.4,11 preexposure vaccination: see table 1 and dosage and administration. preexposure vaccination consists of 3 doses of rabavert 1.0 ml given intramuscularly (deltoid region), 1 each on days 0, 7, and 21 or 281 (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see dosage and administration: postexposure prophylaxis of previously im

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - rabies virus inactivated - powder and solvent for suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for solution for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

United States - English - NLM (National Library of Medicine)

a-s medication solutions - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - rabies virus, quantity: 2.5 iu - injection, powder for - excipient ingredients: monopotassium glutamate; trometamol; sodium chloride; disodium edetate; polygeline; sucrose - active immunisation against rabies virus, including a) pre-exposure immunisation b) post-exposure treatment following exposure to rabies virus.

Kenya - English - Pharmacy and Poisons Board

bilthoven biologicals b.v antonie van leeuwenhoeklaan 9-13, bilthoven, 3721 - inactivated poliomyelitis virus type 1… - suspension for injection - inactivated poliomyelitis virus type 1 -40… - viral vaccines: poliomyelitis vaccines